FDA approval of Vera Therapeutics’ Trutakna makes it first in a new class of medicines designed to block two targets to treat immunoglobulin A nephropathy, an autoimmune disease that can progress to end-stage renal failure. Competition looms from Vertex Pharmaceuticals, on track to receive a November regulatory decision for a drug designed to block the same two proteins.
The post Vera Therapeutics’ First-in-Class Kidney Disease Drug Lands Speedy FDA Approval appeared first on MedCity News.
Beyond the Screen: How Telepsychiatry Must Evolve in theEra of Interventional Psychiatry
Mottsin Thomas, MD, Founder of bonmente Key Takeaways: Telepsychiatry and interventional psychiatry are both expanding rapidly, but existing virtual care workflows are not yet designed
